As of Nov 19, 2026, 1 of 1 active firms rate ATYR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ATYR EPS & revenue forecast
EPS · NEXT QUARTER
$-74.50
Range $-214.80 – $-2.47 · 3 analysts · +1593% YoY
Next period, 3 analysts expect aTyr Pharma, Inc. to earn $-74.50 a share (range $-214.80 – $-2.47), versus $-4.40 a year earlier. Full-year consensus is $-23.97, growing to $-114.76 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering aTyr Pharma, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATYR.
#1
Roger Song
Jefferies · Rank #122
Buy
$17.00+315.6% to target
Overall win rate
43%
+ Follow
#2
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$280.00+6746.0% to target
Overall win rate
30%
+ Follow
#3
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Neutral
No targeton ATYR
Overall win rate
34%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #481
Neutral
$1.00-75.6% to target
Overall win rate
36%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #502
Neutral
$6.00+46.7% to target
Overall win rate
26%
+ Follow
ATYR stock forecast FAQ
What is ATYR's average 12-month price target?+
The 1 active firms with a live target average $3.50 for aTyr Pharma, Inc. over the next 12 months, ranging from a $3.50 high to a $3.50 low, as of Nov 19, 2026.
Is ATYR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover ATYR?+
1 active firms have a recognized rating on aTyr Pharma, Inc. as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ATYR?+
Among analysts who currently cover ATYR, Roger Song of Jefferies has the strongest overall Quantellect track record (Rank #122). Their current call is Buy with a $17.00 target.
What is aTyr Pharma, Inc.'s projected EPS for next quarter?+
The consensus estimate is $-74.50 per share (range $-214.80 – $-2.47) across 3 analysts. Full-year EPS is projected at $-23.97, rising to $-114.76 the following year.
How much revenue is aTyr Pharma, Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ATYR lately?+
As of Nov 19, 2026, 1 of 1 active firms rate ATYR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATYR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.